Biopharma manufacturing company Repligen Corporation (NASDAQ: RGEN) will be announcing earnings results this Tuesday before the bell. Here’s what investors should know.
Repligen beat analysts’ revenue expectations last quarter, reporting revenues of $197.9 million, up 18.1% year on year. It was a mixed quarter for the company, with a solid beat of analysts’ organic revenue estimates but a significant miss of analysts’ full-year EPS guidance estimates.
Is Repligen a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Repligen’s revenue to grow 13.3% year on year, improving from the 10.4% increase it recorded in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Repligen rarely misses Wall Street’s revenue estimates.
Looking at Repligen’s peers in the life sciences tools & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. West Pharmaceutical Services delivered year-on-year revenue growth of 21%, beating analysts’ expectations by 8.4%, and Medpace reported revenues up 26.5%, topping estimates by 1.5%. West Pharmaceutical Services traded up 11.6% following the results while Medpace was down 22.6%.
Read our full analysis of West Pharmaceutical Services’s results here and Medpace’s results here.
There has been positive sentiment among investors in the life sciences tools & services segment, with share prices up 6% on average over the last month. Repligen’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $179.78 (compared to the current share price of $116.84).
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
